Home › Funds › Paulson & Co › MDGL

Paulson & Co position in MDGL

MADRIGAL PHARMACEUTICALS INC · Health Care

Paulson & Co reported holding 1,491,619 shares of MDGL (MADRIGAL PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$751.7M, representing 25.77% of its reported portfolio and ranking #1 among its reported holdings. Paulson & Co has disclosed MDGL holdings in 14 of the last 14 reported quarters, going back to Q2 2023.

Latest position (Q3 2026)1.49M sh
Reported value held$751.72M
Portfolio Weight25.77%
First reportedQ2 2023
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Paulson & Co's MDGL position evolved

Paulson & Co first disclosed a stake in MDGL in Q2 2023 at 350,200 shares (US$80.9M). The position peaked in Q4 2025 at 1,707,522 shares, worth US$994.4M. Across 14 filings, Paulson & Co increased the stake 7 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 1,491,619 shares valued at US$751.7M — an increase of 151,599 shares quarter over quarter.. Notable position changes include a 43% increase in Q3 2023 (shares rose 58% over the following quarter), a 121% increase in Q4 2023 (shares rose 15% over the following quarter), a 61% increase in Q1 2024 (shares rose 5% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2023 350.20K $80.90M New
Q3 2023 500.00K $73.02M Add
Q4 2023 1.11M $255.85M Add
Q1 2024 1.77M $474.00M Add
Q2 2024 1.85M $518.30M Add
Q3 2024 2.04M $392.61M Add
Q4 2024 2.04M $630.10M Hold
Q1 2025 2.10M $695.43M Add
Q2 2025 2.09M $632.37M Hold
Q3 2025 1.91M $874.90M Reduce
Q4 2025 1.71M $994.36M Reduce
Q1 2026 1.39M $728.77M Reduce
Q2 2026 1.34M $719.52M Reduce
Q3 2026 1.49M $751.72M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MDGL and 13F data

MDGL (MADRIGAL PHARMACEUTICALS INC) is a Health Care company. 39 other funds we track also report a position in MDGL — the largest reported positions include BAKER BROS. ADVISORS LP (US$1.08B), Jupiter Topco LLC (US$1.04B), Janus Henderson Group (US$993.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MDGL

All MDGL fund holders →

FAQ

How long has Paulson & Co held MDGL?

Paulson & Co has disclosed MDGL holdings in 14 of the last 14 reported quarters, going back to Q2 2023.

What is Paulson & Co's current position in MDGL?

As of Q3 2026, Paulson & Co holds 1.49M shares of MDGL (MADRIGAL PHARMACEUTICALS INC), valued at $751.72M, representing 25.77% of its reported portfolio and ranking #1.

Has Paulson & Co been buying or selling MDGL?

In the latest 13F filing (Q3 2026), Paulson & Co increased its position in MDGL. The position peaked in Q4 2025 at 1.71M shares.

Which other funds hold MDGL?

Other major institutional holders of MDGL include BAKER BROS. ADVISORS LP, Jupiter Topco LLC, Janus Henderson Group, among 39 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.